RxDoctor Payments DataLook up a doctor →

Philip Malinas, MD

Psychiatry · Reno, NVNPI 1700934825

Payments from drug & device makers

$110,704in general payments, 2019–2025

Across 1,070 payments — averaging $103.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$34K
  • Teva Pharmaceuticals USA, Inc.$24K
  • AbbVie$16K
  • Alkermes, Inc.$13K
  • Eisai Inc.$7K
  • Ironshore Pharmaceuticals Inc.$6K
  • plus $12K from 26 others

What the payments were for

  • Consulting fees$8,8708%
  • Speaking & faculty fees$74,27967%
  • Travel & lodging$7,8717%
  • Food & beverage$19,50818%
  • Education$1750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,704 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.

See all psychiatry providers in Nevada

Medicare billing

Part B allowed, 2024
$144,976
Medicare patients
190
Services billed
1,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine30$347,013
VraylarCariprazine Hcl95$169,344
CaplytaLumateperone Tosylate54$96,169
Invega SustennaPaliperidone Palmitate17$55,116
Lurasidone Hcl93$40,094
LybalviOlanzapine/Samidorphan Malate23$39,153
AuvelityDextromethorphan Hbr/Bupropion20$30,182
TrintellixVortioxetine Hydrobromide31$16,692
RexultiBrexpiprazole12$16,603
QuviviqDaridorexant Hcl33$16,223
Ziprasidone Hcl71$6,892
Alprazolam436$4,807
Clozapine55$4,612
Chlorpromazine Hcl30$4,212
Lisdexamfetamine Dimesylate16$3,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$23,769$347,01330 claims
AbbVieVraylar$15,863$169,34495 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,355$96,16954 claims
Johnson & JohnsonInvega Sustenna$800$55,11617 claims
Alkermes, Inc.Lybalvi$13,276$39,15323 claims
Axsome Therapeutics, Inc.Auvelity$128$30,18220 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$716$16,69231 claims
Otsuka America Pharmaceutical, Inc.Rexulti$33,769$16,60312 claims
Idorsia Pharmaceuticals US IncQuviviq$407$16,22333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 243 psychiatry providers in Nevada.

Other psychiatry in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →